Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. cataract surgery
Show results for
Products
Services
Applications

Companies

News
Articles
Downloads
Videos

Refine by
Date

  • Older

Cataract Surgery Articles & Analysis

30 news found

Two New Innovative Swiss Made EDOF IOLs for Cataract Surgery

Two New Innovative Swiss Made EDOF IOLs for Cataract Surgery

The company Swiss Advanced Vision (SAV-IOL SA) announced today the launch of LUCIDIS and EDEN, two new intraocular lenses (IOLs) for the cataract surgery, both using the Instant Focus EDOF patented technology. ...

BySAV-IOL SA


Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Datagrafic lines 4 Sight Sciences’ OMNI® Surgical System Redu

Sight Sciences’ OMNI® Surgical System Reduces IOP, Daily Fluctuations in IOP and Medication Use, as Shown in Newly Published 12-Month Clinical Datagrafic lines 4 Sight Sciences’ OMNI® Surgical System Redu

The final study results demonstrated that canaloplasty and trabeculotomy performed as an implant-free minimally invasive glaucoma surgery (MIGS) using the OMNI® Surgical System in conjunction with cataract surgery significantly reduced unmedicated mean diurnal intraocular pressure (IOP), medication use and daily fluctuations in IOP in ...

BySight Sciences, Inc.


Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Resultsgrafic lines 4 Sight Sciences

Sight Sciences Reports Fourth Quarter and Full Year 2021 Financial Resultsgrafic lines 4 Sight Sciences

Recent Business Highlights Generated 2021 total revenue of $49.0 million, an increase of 77% compared to the prior year Generated fourth quarter 2021 total revenue of $14.7 million, an increase of 63% compared to the prior year period Expanded total gross margin to 87% in the fourth quarter 2021 versus 74% in the prior year period Received FDA 510(k) Clearance of the TearCare® System ...

BySight Sciences, Inc.


Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

Sight Sciences Announces First Patient Treated in TRIDENT European Trial to Evaluate the OMNI® Surgical System in Pseudophakic Eyes with Open-Angle Glaucoma

The TRIDENT study is a prospective, randomized, multicenter, comparative trial evaluating the safety and effectiveness outcomes, including IOP reduction, for pseudophakic eyes (eyes which had previously undergone cataract surgery) in three study arms: (1) canaloplasty alone using the OMNI Surgical System, (2) sequential canaloplasty followed by trabeculotomy ...

BySight Sciences, Inc.


PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

The second product is a Levofloxacin SR Ocular Implant, an antibiotic-based ocular implant, being developed as a treatment to reduce the risk of infection after cataract surgery. PolyActiva is based in Melbourne, Australia, and has secured venture capital funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) and Yuuwa Capital. ...

ByPolyActiva Pty Ltd.


Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

Sight Sciences Launches “Don’t Wait for Too Late” Awareness Campaign for Glaucoma

” While MIGS first entered the market as an implant-based procedure performed only at the time of cataract surgery, the OMNI® Surgical System*, an implant-free MIGS, is now cleared by the FDA more broadly for use not only in combination with cataract surgery but also as a standalone procedure to lower IOP in adult ...

BySight Sciences, Inc.


Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Announces First Patient Enrolled in Pivotal Clinical Trial Evaluating the Hydrus Microstent in Standalone MIGS for Mild to Moderate Glaucoma

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device intended to lower eye pressure for open-angle glaucoma patients, today announced that the first patient has been enrolled in a pivotal clinical trial evaluating the Hydrus Microstent in patients with mild to moderate open-angle glaucoma, without concurrent ...

ByIvantis, Inc.


TearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the Board

TearLab Corporation Announces Adam Szaronos as President and Chief Executive Officer, and Jim Mazzo as Executive Chairman of the Board

Osmolarity testing enables clinicians to detect visually significant ocular surface disease, and is considered an essential test by the American Society of Cataract and Refractive Surgery. Abnormal osmolarity can adversely impact accuracy of refractive measurements and the TearLab osmolarity test empowers clinicians to accurately diagnose dry eye disease. ...

BySOFIE


Icecure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

Icecure Medical Announces Appointment of Merav Nir Dotan to Vice President Human Resources

Nir Dotan was previously Vice President of Human Resources at Hanita Lenses, a medical device manufacturer and provider of intraocular lens solutions for cataract surgery, and previously served in roles handling recruitment and marketing. ...

ByIceCure Medical Ltd


Microinvasive Glaucoma Surgery with the OMNI Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

Microinvasive Glaucoma Surgery with the OMNI Surgical System is Associated with Diminished Diurnal IOP Fluctuations, a Significant, Independent Risk Factor for Glaucoma Progression

“Post hoc analysis of the GEMINI data suggests that ab-interno canaloplasty plus goniotomy using the OMNI Surgical System combined with cataract surgery has the potential to control IOP fluctuations, a known risk factor for the progression of glaucoma,” said Mark F. ...

BySight Sciences, Inc.


Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Hydrus Microstent Lowers Visual Field Loss by 47% According to New 5-Year Pivotal Trial Data

Combining Hydrus with cataract surgery is an opportunity to treat patients early in their disease state. ...

ByIvantis, Inc.


Bio-Tissue, Inc. Signs National Agreement with EyePro GPO to Afford Members Exclusive Treatment Options for Ocular Surface Disease and Disorders

Bio-Tissue, Inc. Signs National Agreement with EyePro GPO to Afford Members Exclusive Treatment Options for Ocular Surface Disease and Disorders

Bio-Tissue, Inc., a TissueTech company and pioneer in the clinical application of human birth tissue allografts to promote regenerative healing for ocular surface disease and disorders, announced today that it has entered into a Vendor Agreement with EyePro Group Purchasing Organization (GPO), LLC. As such, GPO members can now take advantage of membership purchasing volume discounts to access ...

ByBio-Tissue, Inc.


Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis Announces Settlement of Glaukos Patent Litigation

Ivantis, Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure for open-angle glaucoma patients, today announced that it has entered into an agreement with Glaukos Corporation to settle and dismiss all pending global litigation between them. ...

ByIvantis, Inc.


MediPrint™ Ophthalmics Announces Promising Results From Its Primary Market Research

MediPrint™ Ophthalmics Announces Promising Results From Its Primary Market Research

The post-cataract surgery lens may be able to deliver a combination corticosteroid, NSAID and antibiotic treatment from a single lens. Ophthalmologists will apply the lens after the cataract surgery and patients can wear the lens for one week or longer to deliver the medication, instead of needing to use multiple eye drops every ...

ByMediprint Ophthalmics


LayerBio CEO Presents OcuRing-K at OIS Anterior Innovation Showcase

LayerBio CEO Presents OcuRing-K at OIS Anterior Innovation Showcase

Ken Mandell, Founder and CEO of LayerBio, presented an update on the development of its novel OcuRing-K ketorolac implant for treatment of postoperative pain and inflammation with cataract surgery. To see video, please click ...

ByLayerBio, Inc


Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

Hydrus Microstent Now First MIGS Device Proven With 5-Year Pivotal Trial Data; Results Show Over 60% Reduction in Secondary Glaucoma Surgeries, Sustained Reduction in Medication Use

One of the most important and noteworthy findings of this study is that, of the patients who went on to receive subsequent invasive surgery in the cataract-surgery-only arm, the majority were those who had what we would consider mild glaucoma at baseline. ...

ByIvantis, Inc.


Ivantis Recognized For Innovation, Excellence And Company Culture

Ivantis Recognized For Innovation, Excellence And Company Culture

Ivantis Inc., developer of the novel Hydrus® Microstent, a minimally invasive glaucoma surgery (MIGS) device designed to lower eye pressure in patients with open-angle glaucoma, is proud to be the recipient of multiple awards and recognition this year for its innovation and excellence in helping to change the standard of care for the world’s 80 million glaucoma ...

ByIvantis, Inc.


Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

Hydrus Microstent Receives Highest Designation of Any MIGS Device as Part of AAO Treatment Guidelines

The study was designed to demonstrate the safety and effectiveness of the Hydrus Microstent for lowering intraocular pressure (IOP) in glaucoma patients undergoing planned cataract surgery. Patients were randomized 2:1 to receive cataract surgery plus the Hydrus Microstent or cataract surgery ...

ByIvantis, Inc.


A new type of corneal availability

A new type of corneal availability

Although around 200,000 corneal transplants are performed worldwide each year – and corneal transplant is the most common organ transplant around the globe – close to 13 million people are still on a waiting list for a corneal graft (1), with average delays measured in years. EyeYon Medical, founded by two leading cornea specialists – Ofer Daphna and Arie Markovich – ...

ByEyeYon Medical Ltd


Injectsense Receives Breakthrough Device Program Designation from FDA, Highlights Eye Sensor Performance and Path to Human Studies

Injectsense Receives Breakthrough Device Program Designation from FDA, Highlights Eye Sensor Performance and Path to Human Studies

The injection procedure is very similar to a standard intravitreal eye injection for wet AMD, which is now more common than cataract surgery. These injections are administered several million times every year worldwide. ...

ByInjectsense, Inc.

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical XPRT Industry Products
  • Medical XPRT Industry Software
  • Medical XPRT Industry Training
  • Medical XPRT Industry Services
  • Medical XPRT Industry Applications

Latest

  • Medical XPRT Industry News
  • Medical XPRT Industry Events

Publications

  • Medical XPRT Industry Articles
  • Medical XPRT Industry Books
  • Medical XPRT Industry Magazines
  • Medical XPRT Industry Downloads
  • Medical XPRT Industry Videos

Companies

  • Medical XPRT Industry Companies

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT